Ozempic, Wegovy is connected to cases of rare eye disadvantage, EMA says – National
The European Medicientes Agency has concluded that drug use and Rdo Nordisk’s Weight-West Weight-Lord Weagovy.
It is called Interiton Antenor Optic Neuropathy, a situation may affect 10,000 people who take 10,000 people from the Semaglutide, an active ingredient in the diabetes of Wegovy and Rybelsus, said the Regulator on Friday.
EMA, which started its review in December, said drug use was connected with two increase in the risk of developing status compared to people who do not take medicine.
Naon is inadequate in insufficient blood pressure and causes loss of painful sight over time. It is a very commonly common cause of blindness due to the Optic sensor injury, after glaucoma.
Research has connected the semaglutide to the naon in the past. But it is the first time that the administrator has made a link.
Get weekly health issues
Find the latest medical news and health details set to you every week.
Semagnide belongs to the drug category known as GLP-1 Receptor aconists, which work by helping to control blood sugar levels and cause a sense of fullness.
A large study of about 350,000 disease in the year has been published that the risk of raising Nina are passing from twice after the long-term Magnitide.
EMA said to review all data available in Semaglutide, including data from non-clinics, clinical trials and marketing surveillance.
Endure that he or she refused to renew the prescribed medical information that contains the Semaglutide to enter NANA as a later result. “
Food and drugs, drug management did not immediately respond to the attacker’s request.
